GlassScriptPhysician profile
Jon M Hoversland
NPI 1699822320
$10,941.21
in general payments reported to CMS, 2019-2025
34 companies · $628 in 2025
The $628 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $4,150 · 2021: $4,150 · 2022: $334 · 2023: $442 · 2024: $356 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,136.91 | 2019-2023 | Da Vinci Surgical System |
| Abbvie INC. | $193.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.82 | 2022-2025 | |
| Hologic Sales and Service, LLC | $97.49 | 2022-2023 | Acessa Provu System |
| Astellas Pharma US INC | $91.26 | 2019-2025 | Veozah |
| Indivior INC. | $85.33 | 2024-2025 | Sublocade |
| Exeltis, USA INC. | $83.79 | 2023-2024 | Slynd |
| Exact Sciences Corporation | $82.70 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $77.85 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $75.41 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.38 | 2023-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $62.14 | 2022 | |
| Medtronic, INC. | $58.16 | 2023-2025 | Venaseal |
| Pfizer INC. | $49.94 | 2023-2024 | |
| Novo Nordisk INC | $46.99 | 2024-2025 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $45.69 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $44.84 | 2022-2023 | |
| Axonics, INC. | $38.95 | 2023 | Axonics, Bulkamid |
| Takeda Pharmaceuticals U.S.A., INC. | $38.92 | 2024 | Trintellix |
| Coopersurgical, INC. | $35.33 | 2025 | Paragard T 380a, Endosee |
| Lilly USA, LLC | $35.20 | 2022-2025 | Zepbound, Mounjaro |
| Therapeuticsmd, INC. | $34.18 | 2022 | |
| Tris Pharma INC | $32.67 | 2024 | Dyanavel Xr |
| Organon LLC | $32.57 | 2023 | Nexplanon |
| Insulet Corporation | $29.20 | 2025 | Omnipod |
| Avanos Medical | $27.26 | 2019 | |
| Axsome Therapeutics, INC. | $27.16 | 2022-2025 | Auvelity |
| Minerva Surgical, INC | $26.86 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.35 | 2025 | |
| Dexcom, INC. | $18.85 | 2025 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $18.19 | 2025 | Tremfya |
| Genzyme Corporation | $15.90 | 2025 | |
| Collegium Pharmaceutical, INC. | $15.74 | 2025 | Jornay Pm |
| Amgen INC. | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Hoversland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.